New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
10:51 EDTIPG, APRI, MHFI, NYCBHigh option volume stocks: IPG VXZ APRI MHFI NYCB
News For IPG;APRI;MHFI;NYCB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
12:27 EDTIPGInterpublic Group management to meet with Jefferies
Subscribe for More Information
October 22, 2014
07:13 EDTNYCBNew York Community Bancorp reports Q3 loans originated for investment $2.6B
Reports Q3 non-performing non covered assets fell $30.2M or 17.2% from last year. Reports margin rose three basis points quarter-over-quarter to 2.69% in Q3. Reports Q3 non-covered loans held for investment represented $32.3B, or 91.0%, of total loans at the end of September.
07:05 EDTIPGInterpublic Group reports Q3 EPS 21c, consensus 21c
Subscribe for More Information
07:03 EDTNYCBNew York Community Bancorp reports Q3 cash EPS 29c, consensus 26c
Subscribe for More Information
October 21, 2014
15:35 EDTIPGNotable companies reporting before tomorrow's open
Subscribe for More Information
October 20, 2014
06:13 EDTAPRIApricus Biosciences to host conference call
Subscribe for More Information
05:27 EDTAPRIApricus licensed U.S. development, commercialization rights for fispemifene
Apricus Biosciences announced that it has licensed the U.S. development and commercialization rights for a novel selective estrogen receptor modulator, or SERM, fispemifene, an investigational treatment for urological conditions in men, from Forendo Pharma, a private therapeutics company based in Finland. This license agreement combines Apricus' expertise in men's health with Forendo's established leadership in SERM drug discovery, to advance the development of fispemifene as an investigational treatment for urological conditions in men. Under the terms of the agreement, Forendo and its advisors received an upfront license fee of $12.5M comprised of a $5M cash payment and the issuance of $7.5M in Apricus common stock; approximately 3.6M shares priced at the 360-day average market price of $2.08 per share. The agreement includes additional potential clinical and regulatory milestone payments to Forendo of up to $45M, including for potential FDA approval, as well as potential commercial milestone payments totaling up to $260M, based on achieving specified annual net sales levels up to $1B in the U.S. Apricus will also pay tiered low double-digit royalties based on net sales once the product is commercialized. Apricus will be responsible for the clinical development of fispemifene in the U.S., as well as all future commercialization efforts in the U.S. and its territories.
October 13, 2014
07:13 EDTAPRIApricus Biosciences awarded U.S. patent for RayVa
Apricus Biosciences announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application Serial Number 14/110,348. The patent application generally is directed to methods and compositions for treating Raynaud's phenomenon, including claims related to treating Raynaud's phenomenon that is secondary to systemic sclerosis. Raynaud's phenomenon secondary to systemic sclerosis affects an estimated three to five percent of people in the U.S., disproportionately affecting women and currently has no approved therapy in the U.S., representing an unmet medical need. The FDA has indicated that Apricus' RayVa™ product may qualify for priority review, given the unmet medical need and lack of approved products to treat secondary Raynaud's phenomenon. The FDA will determine if the RayVa New Drug Application qualifies for priority review following its submission, which could occur as early as 2017.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use